Progression of Physical Frailty and the Risk of All-Cause Mortality: Is There a Point of No Return?


Journal

Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062

Informations de publication

Date de publication:
04 2021
Historique:
revised: 04 11 2020
received: 07 08 2020
accepted: 19 11 2020
pubmed: 29 12 2020
medline: 24 9 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

To investigate the rate and patterns of accumulation of frailty manifestations in relationship to all-cause mortality and whether there is a point in the progression of frailty beyond which the process becomes irreversible and death becomes imminent (a.k.a. point of no return). Longitudinal observational study. Community or a non-nursing home residential care setting. Two thousand five hundred and fifty seven robust older adults identified at baseline in 2011 with follow-up for all-cause mortality between 2011 and 2018. Frailty was measured by the physical frailty phenotype. Cox models were used to study the relationships of the number of frailty criteria (0-5) at each point in time and its accumulation patterns with all-cause mortality. Markov state-transition models were used to study annual transitions between health states (i.e., frailty, recovery, and death) after becoming frail among those with frailty onset (n = 373). There was a nonlinear association between greater number of frailty criteria and increasing risk of mortality, with a notable risk acceleration after having accumulated all five criteria (hazard ratio (HR) = 32.6 vs none, 95% confidence interval (CI) = 15.7-67.5). In addition, the risk of one-year mortality tripled, and the likelihood of recovery (i.e., reverting to be robust or pre-frail) halved among those with five frailty criteria compared to those with three or four criteria. A 50% increase in mortality risk was also associated with frailty onset without (vs with) a prior history of pre-frailty (HR = 1.51, 95% CI = 1.20-1.90). Both the number and rate of accumulation of frailty criteria were associated with mortality risk. Although there was insufficient evidence to declare a point of no return, having all five-frailty criteria signals the beginning of a transition toward a point of no return. Ongoing monitoring of frailty progression could aid clinical and personal decision-making regarding timing of intervention and eventual transition from curative to palliative care.

Identifiants

pubmed: 33368158
doi: 10.1111/jgs.16976
pmc: PMC8049969
mid: NIHMS1662820
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

908-915

Subventions

Organisme : NIA NIH HHS
ID : P30 AG021334
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG032947
Pays : United States
Organisme : NIA NIH HHS
ID : U01AG032947
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG021334
Pays : United States

Informations de copyright

© 2020 The American Geriatrics Society.

Références

J Gerontol A Biol Sci Med Sci. 2016 Apr;71(4):489-95
pubmed: 26718984
Ageing Res Rev. 2016 Mar;26:53-61
pubmed: 26674984
J Am Coll Surg. 2010 Jun;210(6):901-8
pubmed: 20510798
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):731-7
pubmed: 17634320
Science. 2012 Oct 19;338(6105):344-8
pubmed: 23087241
Sci Aging Knowledge Environ. 2005 Aug 03;2005(31):pe24
pubmed: 16079413
J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):667-674
pubmed: 30084927
J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(4):564-572
pubmed: 28977651
J Gerontol A Biol Sci Med Sci. 2015 Nov;70(11):1427-34
pubmed: 26297656
J Am Geriatr Soc. 2017 Jan;65(1):179-184
pubmed: 27861714
Eur J Intern Med. 2017 Nov;45:84-90
pubmed: 28993099
Curr Geriatr Rep. 2019 Jun;8(2):97-106
pubmed: 31815092
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
BMJ Support Palliat Care. 2015 Dec;5(4):335-42
pubmed: 26586682
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
Clin Geriatr Med. 2011 Feb;27(1):1-15
pubmed: 21093718
J Gerontol A Biol Sci Med Sci. 2006 Mar;61(3):262-6
pubmed: 16567375
Arch Surg. 2012 Feb;147(2):190-3
pubmed: 22351919
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
J Gerontol A Biol Sci Med Sci. 2008 Sep;63(9):984-90
pubmed: 18840805
Am J Transplant. 2013 Aug;13(8):2091-5
pubmed: 23731461
J Gerontol B Psychol Sci Soc Sci. 2014 Nov;69 Suppl 1:S1-7
pubmed: 25342818

Auteurs

Qian-Li Xue (QL)

Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Center on Aging and Health, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Karen Bandeen-Roche (K)

Center on Aging and Health, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Jing Tian (J)

Center on Aging and Health, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Judith D Kasper (JD)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Linda P Fried (LP)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH